SLXN
NASDAQSilexion Therapeutics Corp
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks69+300%
2026-03-012026-08-23
Mix3990d
- SEC Filings24(62%)
- Other9(23%)
- Insider3(8%)
- Offering2(5%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form DEF 14A filed by Silexion Therapeutics CorpDEF 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics CorpSCHEDULE 13D/A - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSEC Form SCHEDULE 13G filed by Silexion Therapeutics CorpSCHEDULE 13G - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSEC Form PRE 14A filed by Silexion Therapeutics CorpPRE 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form 10-Q filed by Silexion Therapeutics Corp10-Q - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateSuccessfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 following clinical trial authorizations from regulators in both Israel and Germany Expanded the therapeutic profile of SIL204 with new preclinical immuno-oncology data supporting a coordinated immune-sensitization signature across three key immune pathways and four KRAS mutations, reinforcing the rationale for future combination with anti-PD-(L)1 checkpoint inhibitor therapies Advanced operational and financial readiness for the Phase 2/3 program, including initiation of GMP clini
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form 424B4 filed by Silexion Therapeutics Corp424B4 - Silexion Therapeutics Corp (0002022416) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Silexion Therapeutics CorpSCHEDULE 13G/A - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSEC Form EFFECT filed by Silexion Therapeutics CorpEFFECT - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Announces Pricing of $2.5 Million Public OfferingGRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company’s ordinary shares (or ordinary share equivalents) and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of $0.65 per share (or per ordinary share equivalent) and accompanying warrants. The series E warrants will have an exercise price of $0.65 per share, will be exercisable immediately upon issuance and
- SECAmendment: SEC Form S-1/A filed by Silexion Therapeutics CorpS-1/A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form S-1 filed by Silexion Therapeutics CorpS-1 - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven CancersNew preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune "death receptor," and statistically significant downregulation of HLA-G, an established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines representing three distinct KRAS mutations (G12D, G12V, and G12C) Combined with previously reported MHC-I upregulation, findings support a coordinated immune-sensitization signature across three key immune pathways - increased antigen presentation, restored susceptibility to immune-mediated apoptosis, and reduced immune checkpoint activity - and reinforce the scientific rationale for co
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Other Events8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Leadership Update8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical CenterSuccessful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center ("TASMC" or "Ichilov"), one of Israel’s largest and most prominent academic medical centers, clears the site to commence patient screening Milestone marks the start of Silexion’s transition of the SIL204 program from regulatory preparation into active clinical execution, following the Company’s previously announced regulatory authorizations from the Israeli Ministry of Health and Germany’s Federal Institute for Drugs and Medical Devices (BfArM) With site initiation complete, patient screening at TASMC is expected to commence in the coming weeks, with first patient dosing anticipated to follo
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form DEFA14A filed by Silexion Therapeutics CorpDEFA14A - Silexion Therapeutics Corp (0002022416) (Filer)
SLXN FAQ
4 questionsWhere does SLXN stock trade?
Silexion Therapeutics Corp (SLXN) is listed on NASDAQ.What sector and industry is SLXN in?
Silexion Therapeutics Corp operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to SLXN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SLXN side-by-side with any of them on Quantisnow.How can I track SLXN on Quantisnow?
Quantisnow aggregates Silexion Therapeutics Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLXN to receive live email and push alerts on every new disclosure.